NCT02076451View on ClinicalTrials.gov

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Advanced Solid TumorLymphoma
Interventions
DRUG

DS-8273a

DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks

Trial Locations (1)

37203

Sarah Cannon Research Institute / Tennesee Oncology, Nashville

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY